Tumors With KRAS G12C Mutation Respond to Adagrasib and Using Toripalimab to Treat Stage III Lung Cancer: The ASCO Plenary Series
Read about 2 studies from the April 2023 ASCO Plenary Series, which highlights the use of adagrasib to target several solid tumors with a KRAS G12C mutation and the use of toripalimab to treat stage III non-small cell lung cancer before and after surgery.